96

Bioinformatics of the Brain

[9] B. C. Prager, S. Bhargava, and V. Mahadev et al., “Glioblastoma stem

cells: driving resilience through chaos,” Trends in Cancer, vol. 6, no. 3,

pp. 223–235, 2020.

[10] M. Del Bene, D. Osti, and S. Faletti et al., “Extracellular vesicles: the

key for precision medicine in glioblastoma,” Neuro-Oncology, vol. 24,

no. 2, pp. 184–196, 2021.

[11] T. Simon, E. Jackson, and G. Giamas, “Breaking through the glioblas-

toma micro-environment via extracellular vesicles,” Oncogene, vol. 39,

no. 23, pp. 4477–4490, 2020.

[12] A. Yekula, A. Yekula, and K. Muralidharan et al., “Extracellular vesicles

in glioblastoma tumor microenvironment,” Frontiers in Immunology,

vol. 10, p. 3137, 2020.

[13] D. M. Mallawaaratchy, S. Hallal, and B. Russell et al., “Comprehensive

proteome profiling of glioblastoma-derived extracellular vesicles identi-

fies markers for more aggressive disease,” Journal of Neuro-oncology,

vol. 131, pp. 233–244, 2017.

[14] F. L. Ricklefs, Q. Alayo, and H. Krenzlin et al., “Immune evasion medi-

ated by PD-L1 on glioblastoma-derived extracellular vesicles,” Science

Advances, vol. 4, no. 3, p. eaar2766, 2018.

[15] A. Yekula, V. R. Minciacchi, and M. Morello et al., “Large and small ex-

tracellular vesicles released by glioma cells in vitro and in vivo,” Journal

of Extracellular Vesicles, vol. 9, no. 1, p. 1689784, 2020.

[16] J. Tang, P. Flomenberg, and L. Harshyne et al., “Glioblastoma patients

exhibit circulating tumor-specific CD8+ T Cells,” Clinical Cancer Re-

search, vol. 11, no. 14, pp. 5292–5299, 2005.

[17] J. Litak, M. Mazurek, and C. Grochowski et al., “PD-L1/PD-1 axis in

glioblastoma multiforme,” International Journal of Molecular Sciences,

vol. 20, no. 21, p. 5347, 2019.

[18] Y. Liu, R. Carlsson, and M. Ambjørn et al., “PD-L1 expression by neu-

rons nearby tumors ındicates better prognosis in glioblastoma patients,”

Journal of Neuroscience, vol. 33, no. 35, pp. 14231–14245, 2013.

[19] S. Lim, D. Kim, and S. Ju et al., “Glioblastoma-secreted soluble

CD44 activates tau pathology in the brain,” Experimental & Molecu-

lar Medicine, vol. 50, no. 4, pp. 1–11, 2018.

[20] P. Jarabo, C. de Pablo, and H. Herranz et al., “Insulin signaling medi-

ates neurodegeneration in glioma,” Life Science Alliance, vol. 4, no. 3,

p. e202000693, 2021.